This article was originally published in The Tan Sheet
Parties involved in ERSP cases have the opportunity to participate in the review process under specific circumstances, counter to comments included in an article in the Oct. 16 issue of "The Tan Sheet" (1"The Tan Sheet" Oct. 16, 2006, p. 13). "Under ERSP's policies and procedures, the person or legal entity that initiates the inquiry has the option of actively participating in the review process, but is not required to do so," ERSP Director Peter Marinello tells "The Tan Sheet." When parties involved in cases choose to participate, they have access to all non-confidential submissions and can contribute comments to the record, Marinello says. However, "parties that elect to remain anonymous may not review the submissions or contribute to the case record," he adds...
You may also be interested in...
Dietary supplement and nutritional product firms challenging competitors' claims have several options more cost-effective than litigation, advises Ivan Wasserman, a partner at Kelly Drye Collier Shannon (Washington, D.C.)
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.
TytoCare has raised $50m in funding, which will be used to expand the reach of its telehealth solutions.